 |
 | Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Desig |  |
|
RSS FEED
|
|
Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), announced that the U.S. Food and Drug Administration ("FDA") has granted orphan drug designation for cysteamine bitartrate ("cysteamine") for the treatment of Huntington's disease ("HD"). Cysteamine is currently approved by the FDA and European Medicines Agency ("EMEA") to treat nephropathic cystinosis ("cystinosis"), a rare lysosomal storage disease.
Read more... |
|||||||||||
|
|||||||||||||
 |
 | Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Desig | |
|
||
|
|
|
Site Map
|
Sitemap |